An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients - Gilleen, James; Farah, Yakub; Davison, Cate; Kerins, Sarah; Valdearenas, Lorena; Uz, Tolga; Lahu, Gez; Tsai, Max; Ogrinc, Frank; Reichenberg, Avi; Williams, Steve C.; Mehta, Mitul A.; et al. (Psychopharmacology, 2021)
Keywords: Adult; Aminopyridines - pharmacology; AMP; Analysis; Animal models; Animals; Behavior; Benzamides - pharmacology; Biomedical and Life Sciences; Biomedicine; Brain - drug effects; Brain mapping; Cognition - drug effects; Cognition Disorders - drug therapy; Cognition Disorders - physiopathology; Cognitive ability; Control; Cross-Over Studies; Cyclic AMP; Cyclopropanes - pharmacology; Data processing; Dosage; Dosage and administration; Double-Blind Method; Double-blind studies; Drug therapy; Episodic memory; Female; Functional magnetic resonance imaging; Humans; Language; Male; Memory; Memory, Episodic; Memory, Short-Term - drug effects; Mental disorders; Mental task performance; Middle Aged; Neurosciences; Original Investigation; Patient outcomes; Patients; Pharmacology/Toxicology; Phosphodiesterase; Phosphodiesterase 4 Inhibitors - pharmacology; Phosphodiesterases; Placebos; Prefrontal cortex; Prefrontal Cortex - drug effects; Psychiatry; Psychological aspects; Roflumilast; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - physiopathology; Schizophrenics; Short term memory; Spatial memory; Statistical analysis; United Kingdom; fMRI; PDE4 inhibition; PDE4; Memory; CIAS; Schizophrenia; Cognition; Cognitive enhancement; Roflumilast